SELECTA BIOSCI. DL -,0001
SELECTA BIOSCI. DL -,0001
Share · US8162121045 · SELB · A2AML0 (LSSI)
Overview Financial Indicators
No Price
n/a

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
- - - - -1,87 % 0,32 % -80,72 %

Company Profile for SELECTA BIOSCI. DL -,0001 Share

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising SEL-313, a product candidate in preclinical stage to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to evaluate the appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and products for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat primary biliary cholangitis and other autoimmune diseases. The company has license and collaboration agreements with Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum; Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Ginkgo Bioworks Holdings, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

Invested Funds

The following funds have invested in: SELECTA BIOSCI. DL -,0001 invested:

Fund
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. in million
15,70
Percentage (%)
0,04 %

Company Data

Name SELECTA BIOSCI. DL -,0001
Company Selecta Biosciences, Inc.
Symbol SELB
Website https://selectabio.com
Primary Exchange LSSI Lang & Schwarz
WKN A2AML0
ISIN US8162121045
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Dr. Carsten Brunn Ph.D.
Market Capitalization 135 Mio
Country United States of America
Currency EUR
Employees 0,1 T
Address 65 Grove Street, 02472 Watertown
IPO Date 2016-06-22

Ticker Symbols

Name Symbol
NASDAQ SELB

More Shares

Investors who SELECTA BIOSCI. DL -,0001 hold also have the following shares in their portfolio:
AMGEN INC
AMGEN INC Share
AUTODESK INC
AUTODESK INC Share
BAYN GROUP AB
BAYN GROUP AB Share
CISCO SYSTEMS INC
CISCO SYSTEMS INC Share
COSTCO WHOLESALE CORP
COSTCO WHOLESALE CORP Share
ELECTRONIC ARTS INC
ELECTRONIC ARTS INC Share
FIDELITY-EM.MKT.FO.AACCDL
FIDELITY-EM.MKT.FO.AACCDL Fund
FIRST ABU DHABI BANK P.J.S.C. 2.600% NTS 09/04/2022
FIRST ABU DHABI BANK P.J.S.C. 2.600% NTS 09/04/2022 Bond
GILAT SATELLITE NETWORKS LTDNARY SHARES
GILAT SATELLITE NETWORKS LTDNARY SHARES Share
INTEL CORP
INTEL CORP Share
JPMORGAN CHASE & CO
JPMORGAN CHASE & CO Share
MICROSOFT CORP
MICROSOFT CORP Share
NXP SEMICONDUCTORS NV
NXP SEMICONDUCTORS NV Share
WALGREENS BOOTS ALLIANCE INC
WALGREENS BOOTS ALLIANCE INC Share
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025